TB-500: Uses, Benefits & Research

What is TB-500?

TB-500 is a synthetic version of a 43-amino acid fragment of thymosin beta-4, a naturally occurring protein found in nearly all human and animal cells. With a molecular weight of approximately 4,963 Da, TB-500 is marketed as a tissue repair and regeneration peptide, primarily administered via subcutaneous injection. It is important to note that TB-500 and full thymosin beta-4 are often conflated in marketing and even in some literature — many claims of “100+ human studies” originate from this conflation. Actual TB-500-specific human data is significantly thinner than commonly represented.

TB-500 is not FDA-approved and is currently classified as FDA Category 2 (restricted from compounding), though reclassification to Category 1 has been announced but not yet finalized. It is not approved in any major regulatory jurisdiction.

Mechanism of Action

TB-500’s proposed mechanisms are primarily established through in vitro and animal studies, with no direct human pharmacodynamic studies confirming its mechanism of action.

The primary proposed mechanism involves binding to G-actin, which modulates the actin cytoskeleton and affects cell motility. This actin-binding activity is thought to facilitate cell migration to injury sites — a critical step in tissue repair. Secondary mechanisms include upregulation of VEGF in endothelial cells (promoting angiogenesis), downregulation of pro-inflammatory cytokines including IL-6 and TNF-alpha, potential mobilization of stem and progenitor cells, and anti-apoptotic effects observed in cardiac injury models.

All mechanistic understanding derives from cell culture and animal studies. Species differences in tissue repair mechanisms and immune response limit the direct translation of these findings to human biology.

Clinical Evidence

Human Studies

Human evidence for TB-500 specifically is extremely limited:

• Zero published RCTs specifically on TB-500
• One registered trial (NCT00832091) — a Phase I/II study of thymosin beta-4 in venous stasis disease that was completed but results were never fully published. It remains unclear whether this trial used the TB-500 fragment or the full protein.
• 2-3 published case reports with small patient numbers
• Anecdotal compounding pharmacy reports without scientific rigor

The frequently cited “100+ human studies” claim conflates TB-500 with full thymosin beta-4, which has been studied more extensively but is a distinct compound.

Preclinical Research

Animal evidence is considerably stronger, though species translation limitations apply:

• Wound healing (rat): Accelerated closure with reduced scarring
• Cardiac injury (rat): Reduced infarct size and improved cardiac function
• Corneal injury (rabbit): Improved corneal healing
• Spinal cord injury (rat): Improved functional recovery
• Tendon injury (horse): Improved tendon healing outcomes
• Stroke model (rat): Neuroprotective effects observed

These preclinical findings are promising but remain unvalidated in humans.

Drug Interactions & Contraindications

No formal drug interaction studies have been conducted for TB-500 in humans. All interactions are theoretical, based on the proposed mechanism of action:

• Anticoagulants/Antiplatelets: Angiogenesis promotion may affect bleeding risk
• Immunosuppressants: TB-4 has immunomodulatory properties that could interfere
• Cancer therapeutics and VEGF inhibitors: Angiogenesis promotion could counteract anti-cancer therapies
• NSAIDs: May interact with the inflammatory response pathway

TB-500 is contraindicated in patients with active cancer due to the theoretical risk that angiogenesis promotion could fuel tumor growth. It should not be used during pregnancy, and patients with cardiovascular disease should exercise caution.

Safety & Side Effects

Safety data for TB-500 is very limited. The Phase I/II venous stasis trial (NCT00832091) reported general tolerability, but specific adverse events were not fully published. Topical thymosin beta-4 studies showed low irritation and good skin tolerability.

Theoretical safety concerns based on the mechanism of action include potential cancer risk (from angiogenesis promotion), immune modulation effects, cardiovascular effects from blood vessel formation changes, and possible bleeding risk. None of these have been validated or ruled out through adequate human safety studies.

The compound is currently FDA Category 2 (restricted from compounding), with a pending reclassification announcement. No large-scale safety studies have been published.

Honest Bottom Line

TB-500 (thymosin beta-4 fragment) has generated significant interest based on promising animal data showing tissue repair, anti-inflammatory, and pro-angiogenic effects. However, as of March 2026, human evidence is extremely limited — zero published RCTs specifically on TB-500, with most “human study” claims conflating this fragment with the full thymosin beta-4 protein. The regulatory status remains Category 2 (restricted), though reclassification may change this. The one registered human trial (NCT00832091) was completed but results are not fully published, leaving significant questions about human efficacy. Animal data is encouraging but species differences in tissue repair mechanisms limit translation. Patients considering TB-500 should understand they are using a compound with minimal human safety and efficacy data, no FDA approval, and significant regulatory uncertainty.